Our findings affirm that the presence of this mutation in breast cancer patients is associated with distinct clinical presentation: older at diagnosis, higher prevalence of progesterone receptors in the tumor tissue, and, most notably, the patients are more commonly diagnosed with metastatic disease. Here, PGR is linked to neoplasm.